Publication:
Autoimmune Diseases in Patients With Myotonic Dystrophy Type 2

dc.contributor.authorPeric, Stojan (35750481700)
dc.contributor.authorZlatar, Jelena (57826101100)
dc.contributor.authorNikolic, Luka (57825768600)
dc.contributor.authorIvanovic, Vukan (57211858030)
dc.contributor.authorPesovic, Jovan (15725996300)
dc.contributor.authorPetrovic Djordjevic, Ivana (57815873500)
dc.contributor.authorSreckovic, Svetlana (55979299300)
dc.contributor.authorSavic-Pavicevic, Dusanka (57212301497)
dc.contributor.authorMeola, Giovanni (7005543642)
dc.contributor.authorRakocevic-Stojanovic, Vidosava (6603893359)
dc.date.accessioned2025-07-02T11:59:02Z
dc.date.available2025-07-02T11:59:02Z
dc.date.issued2022
dc.description.abstractIntroduction: Myotonic dystrophy type 2 (DM2) is a rare autosomal dominant multisystemic disease with highly variable clinical presentation. Several case reports and one cohort study suggested a significant association between DM2 and autoimmune diseases (AIDs). Aim: The aim of this study is to analyze the frequency and type of AIDs in patients with DM2 from the Serbian DM registry. Patients and Methods: A total of 131 patients with DM2 from 108 families were included, [62.6% women, mean age at DM2 onset 40.4 (with standard deviation 13) years, age at entering the registry 52 (12.8) years, and age at analysis 58.4 (12.8) years]. Data were obtained from Akhenaten, the Serbian registry for DM, and through the hospital electronic data system. Results: Upon entering the registry, 35 (26.7%) of the 131 patients with DM2 had AIDs including Hashimoto thyroiditis (18.1%), rheumatoid arthritis, diabetes mellitus type 1, systemic lupus, Sjogren's disease, localized scleroderma, psoriasis, celiac disease, Graves's disease, neuromyelitis optica, myasthenia gravis, and Guillain-Barre syndrome. At the time of data analysis, one additional patient developed new AIDs, so eventually, 36 (28.8%) of 125 DM2 survivors had AIDs. Antinuclear antibodies (ANAs) were found in 14 (10.7%) of 63 tested patients, including 12 without defined corresponding AID (all in low titers, 1:40 to 1:160). Antineutrophil cytoplasmic antibodies (ANCAs) were negative in all 50 tested cases. The percentage of women was significantly higher among patients with AIDs (82.9% vs. 55.2%, p <0.01). Conclusion: AIDs were present in as high as 30% of the patients with DM2. Thus, screening for AIDs in DM2 seems reasonable. Presence of AIDs and/or ANAs may lead to under-diagnosis of DM2. Copyright © 2022 Peric, Zlatar, Nikolic, Ivanovic, Pesovic, Petrovic Djordjevic, Sreckovic, Savic-Pavicevic, Meola and Rakocevic-Stojanovic.
dc.identifier.urihttps://doi.org/10.3389/fneur.2022.932883
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85135206566&doi=10.3389%2ffneur.2022.932883&partnerID=40&md5=fbbfedbe7ef75893ced228fb249da31f
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/12066
dc.subjectantineutrophil cytoplasmic antibodies
dc.subjectantinuclear antibodies
dc.subjectautoimmune diseases
dc.subjectHashimoto autoimmune thyroiditis
dc.subjectmyotonic dystrophy type 2 (DM2)
dc.titleAutoimmune Diseases in Patients With Myotonic Dystrophy Type 2
dspace.entity.typePublication

Files